These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 27422324)

  • 21. Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity.
    Stewart JD; Horvath R; Baruffini E; Ferrero I; Bulst S; Watkins PB; Fontana RJ; Day CP; Chinnery PF
    Hepatology; 2010 Nov; 52(5):1791-6. PubMed ID: 21038416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Juvenile Alpers disease.
    Wiltshire E; Davidzon G; DiMauro S; Akman HO; Sadleir L; Haas L; Zuccollo J; McEwen A; Thorburn DR
    Arch Neurol; 2008 Jan; 65(1):121-4. PubMed ID: 18195149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alpers syndrome: progressive neuronal degeneration of children with liver disease.
    Gordon N
    Dev Med Child Neurol; 2006 Dec; 48(12):1001-3. PubMed ID: 17109792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Valproate-induced liver failure in one of two siblings with Alpers disease.
    Schwabe MJ; Dobyns WB; Burke B; Armstrong DL
    Pediatr Neurol; 1997 May; 16(4):337-43. PubMed ID: 9258971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Partial status epilepticus - rapid genetic diagnosis of Alpers' disease.
    McCoy B; Owens C; Howley R; Ryan S; King M; Farrell MA; Lynch BJ
    Eur J Paediatr Neurol; 2011 Nov; 15(6):558-62. PubMed ID: 21704543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpers syndrome with mutations in POLG: clinical and investigative features.
    Hunter MF; Peters H; Salemi R; Thorburn D; Mackay MT
    Pediatr Neurol; 2011 Nov; 45(5):311-8. PubMed ID: 22000311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpers-huttenlocher syndrome: origins of clinicopathologic recognition.
    Rust RS
    Pediatr Neurol; 2013 Mar; 48(3):165-6. PubMed ID: 23419466
    [No Abstract]   [Full Text] [Related]  

  • 28. POLG gene mutation. Clinico-neuropathological study.
    Tarka S; Laure-Kamionowska M; Wierzba-Bobrowicz T; Witulska K; Ciara E; Szymańska K; Krajewski P; Stępień T; Acewicz A; Felczak P
    Folia Neuropathol; 2020; 58(4):386-392. PubMed ID: 33480243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity.
    Bicknese AR; May W; Hickey WF; Dodson WE
    Ann Neurol; 1992 Dec; 32(6):767-75. PubMed ID: 1471867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compound heterozygous polymerase gamma gene mutation in a patient with Alpers disease.
    Cardenas JF; Amato RS
    Semin Pediatr Neurol; 2010 Mar; 17(1):62-4. PubMed ID: 20434700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. POLG mutations and Alpers syndrome.
    Davidzon G; Mancuso M; Ferraris S; Quinzii C; Hirano M; Peters HL; Kirby D; Thorburn DR; DiMauro S
    Ann Neurol; 2005 Jun; 57(6):921-3. PubMed ID: 15929042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Central-peripheral sensory axonopathy in a juvenile case of Alpers-Huttenlocher disease.
    Simonati A; Filosto M; Tomelleri G; Savio C; Tonin P; Polo A; Rizzuto N
    J Neurol; 2003 Jun; 250(6):702-6. PubMed ID: 12796833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnesium treatment for patients with refractory status epilepticus due to POLG1-mutations.
    Visser NA; Braun KP; Leijten FS; van Nieuwenhuizen O; Wokke JH; van den Bergh WM
    J Neurol; 2011 Feb; 258(2):218-22. PubMed ID: 20803213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance to valproic acid as predictor of treatment resistance in genetic generalized epilepsies.
    Gesche J; Khanevski M; Solberg C; Beier CP
    Epilepsia; 2017 Apr; 58(4):e64-e69. PubMed ID: 28230254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clonally expanded mitochondrial DNA mutations in epileptic individuals with mutated DNA polymerase gamma.
    Zsurka G; Baron M; Stewart JD; Kornblum C; Bös M; Sassen R; Taylor RW; Elger CE; Chinnery PF; Kunz WS
    J Neuropathol Exp Neurol; 2008 Sep; 67(9):857-66. PubMed ID: 18716558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpers syndrome: an unusual etiology of failure to thrive.
    Mangalat N; Tatevian N; Bhattacharjee M; Rhoads JM
    Ultrastruct Pathol; 2012 Aug; 36(4):219-21. PubMed ID: 22849523
    [No Abstract]   [Full Text] [Related]  

  • 37. Molecular diagnosis of Alpers syndrome.
    Nguyen KV; Sharief FS; Chan SS; Copeland WC; Naviaux RK
    J Hepatol; 2006 Jul; 45(1):108-16. PubMed ID: 16545482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Alpers-Huttenlocher syndrome caused by a novel compound heterozygous mutation of POLG gene: a case report].
    Zhang YF; Wang JT; Gao JB; Lyu YY; Liang JM; Jia FY; Chen YB; Hao YP
    Zhongguo Dang Dai Er Ke Za Zhi; 2017 May; 19(5):498-501. PubMed ID: 28506336
    [No Abstract]   [Full Text] [Related]  

  • 39. Juvenile-onset Alpers syndrome: interpreting MRI findings.
    Visser NA; Braun KP; van den Bergh WM; Leijten FS; Willems CR; Ramos L; van den Bosch BJ; Smeets HJ; Wokke JH
    Neurology; 2010 Apr; 74(15):1231-3. PubMed ID: 20385895
    [No Abstract]   [Full Text] [Related]  

  • 40. Early-life epileptic encephalopathy secondary to SZT2 pathogenic recessive variants.
    Venkatesan C; Angle B; Millichap JJ
    Epileptic Disord; 2016 Jun; 18(2):195-200. PubMed ID: 27248490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.